Adropin and MOTS-c as new peptides: Do levels change in neurodegenerative diseases and ischemic stroke?

Saçmacı H, Çakır M, Özcan SS

Journal of biochemical and molecular toxicology27 Oct 2022Cited by 4 (Europe PMC)

PMID36303331DOI10.1002/jbt.23246PepBankPUB-36303331

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In patients with acute ischemic stroke, plasma MOTS‑c levels were lower than in controls.
In plain wordsPeople with acute ischemic stroke had lower levels of the body's own MOTS‑c in blood than controls.
Peptide
MOTS-c
Outcome
DecreasePlasma MOTS-c in acute ischemic stroke
Study
n: not reported in source
Comparator
Controls
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Plasma adropin levels were decreased in the AD group and decreased in MOTS-c, AIS, and AD groups compared to the control (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This study provides new information about adropin may be potentially important markers in AD and MOTS-C in AIS and AD.
Summary · context
This study was conducted with 32 patients from each subgroup and group-appropriate controls.
Summary · context
Additionally, plasma adropin, MOTS-c, NSE, and NF-L levels were evaluated by the ELISA method.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3630333101
02HumanEndogenous levelObservational studyOther
In patients with Alzheimer's disease, plasma MOTS‑c levels were lower than in controls.
In plain wordsPeople with Alzheimer's disease had lower levels of the body's own MOTS‑c in blood than controls.
Peptide
MOTS-c
Outcome
DecreasePlasma MOTS-c in Alzheimer's disease
Study
n: not reported in source
Comparator
Controls
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Plasma adropin levels were decreased in the AD group and decreased in MOTS-c, AIS, and AD groups compared to the control (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This study provides new information about adropin may be potentially important markers in AD and MOTS-C in AIS and AD.
Summary · context
This study was conducted with 32 patients from each subgroup and group-appropriate controls.
Summary · context
Additionally, plasma adropin, MOTS-c, NSE, and NF-L levels were evaluated by the ELISA method.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3630333102
03HumanEndogenous levelObservational studyOther
In patients with multiple sclerosis, plasma MOTS‑c levels did not differ significantly from controls.
In plain wordsPeople with multiple sclerosis had similar levels of the body's own MOTS‑c in blood as controls.
Peptide
MOTS-c
Outcome
No significant changePlasma MOTS-c in multiple sclerosis
Study
n: not reported in source
Comparator
Controls
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Similar values were found in the MS group compared to its control (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted with 32 patients from each subgroup and group-appropriate controls.
Summary · context
Additionally, plasma adropin, MOTS-c, NSE, and NF-L levels were evaluated by the ELISA method.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3630333103
04HumanEndogenous levelObservational studyOther
Plasma MOTS‑c levels correlated positively with platelet levels.
In plain wordsHigher levels of the body's own MOTS‑c were linked to higher platelet counts.
Peptide
MOTS-c
Outcome
IncreaseCorrelation of MOTS-c with platelet count
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
In correlation analysis of these markers with laboratory parameters, while platelet and cholesterol levels were negatively correlated with adropin levels; platelet, lymphocyte, and triglyceride levels were positively correlated with MOTS-c (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted with 32 patients from each subgroup and group-appropriate controls.
Summary · context
Additionally, plasma adropin, MOTS-c, NSE, and NF-L levels were evaluated by the ELISA method.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3630333104
05HumanEndogenous levelObservational studyOther
Plasma MOTS‑c levels correlated positively with lymphocyte levels.
In plain wordsHigher levels of the body's own MOTS‑c were linked to higher lymphocyte counts.
Peptide
MOTS-c
Outcome
IncreaseCorrelation of MOTS-c with lymphocyte count
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
In correlation analysis of these markers with laboratory parameters, while platelet and cholesterol levels were negatively correlated with adropin levels; platelet, lymphocyte, and triglyceride levels were positively correlated with MOTS-c (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted with 32 patients from each subgroup and group-appropriate controls.
Summary · context
Additionally, plasma adropin, MOTS-c, NSE, and NF-L levels were evaluated by the ELISA method.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3630333105
06HumanEndogenous levelObservational studyOther
Plasma MOTS‑c levels correlated positively with triglyceride levels.
In plain wordsHigher levels of the body's own MOTS‑c were linked to higher triglyceride levels.
Peptide
MOTS-c
Outcome
IncreaseCorrelation of MOTS-c with triglycerides
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
In correlation analysis of these markers with laboratory parameters, while platelet and cholesterol levels were negatively correlated with adropin levels; platelet, lymphocyte, and triglyceride levels were positively correlated with MOTS-c (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted with 32 patients from each subgroup and group-appropriate controls.
Summary · context
Additionally, plasma adropin, MOTS-c, NSE, and NF-L levels were evaluated by the ELISA method.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3630333106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.